Literature DB >> 10438972

Generation of anti-p53 Fab fragments from individuals with colorectal cancer using phage display.

D W Coomber1, N J Hawkins, M A Clark, R L Ward.   

Abstract

Although many individuals with malignancy develop Abs against p53, little is currently known of the structural features, V gene usage, and degree of somatic mutation of these Abs. Such information is critical to any meaningful understanding of the nature and significance of this humoral immune response to p53. We have constructed phage display libraries from six individuals with colorectal cancer and a demonstrable serum immune response against p53. Following panning with recombinant p53, a total of 43 binding Fab were identified. Four of these Abs bound with high affinity to wild-type denatured p53 (1.19 x 10-8 - 1.57 x 10-8), as determined by BIAcore analysis, and were highly specific for both recombinant and cell line-derived p53, as determined by ELISA and immunoprecipitation. Epitope mapping showed they were reactive with the N terminus of human p53 between residues 27 and 44. Sequence analysis showed that the heavy chains were derived from the VH1 gene family, and the light chains from VL4. The pattern of replacement and silent mutations in the Fab sequence indicated that negative selection had occurred in the framework regions of all the VH genes. We show that lymphocytes from individuals with cancer represent a valuable source of high affinity human Abs against p53. This approach provides an opportunity to examine the genetic structure of these naturally occurring Abs, and to draw inferences regarding the nature of the immune response that produced them. Abs identified in this way have a number of potential therapeutic applications.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10438972

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  3 in total

1.  Anti-p21 autoantibodies detected in colorectal cancer patients: A proof of concept study.

Authors:  Faraz Bishehsari; Johannes S Gach; Naomi Akagi; Molly K Webber; Jessica Bauer; Barbara H Jung
Journal:  Oncoimmunology       Date:  2014-11-14       Impact factor: 8.110

2.  Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy.

Authors:  Mirna Lechpammer; Josip Lukac; Stanislav Lechpammer; Dujo Kovacević; Massimo Loda; Zvonko Kusić
Journal:  Int J Colorectal Dis       Date:  2003-11-21       Impact factor: 2.571

3.  Design and activity of a murine and humanized anti-CEACAM6 single-chain variable fragment in the treatment of pancreatic cancer.

Authors:  Christopher J Riley; Kevin P Engelhardt; Jose W Saldanha; Wenqing Qi; Laurence S Cooke; Yingting Zhu; Satya T Narayan; Kishore Shakalya; Kimiko Della Croce; Ivan G Georgiev; Raymond B Nagle; Harinder Garewal; Daniel D Von Hoff; Daruka Mahadevan
Journal:  Cancer Res       Date:  2009-02-24       Impact factor: 12.701

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.